anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1. Tablet for sucking containing ambroxol, based on sugar alcohols as the matrix material, characterised in that it contains a pharmaceutically acceptable laminar silicate and a polyethyleneglycol optionally together with other pharmaceutical excipients, taste enhancers or flavourings. 2. Tablet for sucking containing ambroxol according to claim 1, characterised in that the laminar silicate is talc. 3. Tablet for sucking containing ambroxol according to claim 1 or 2, characterised in that the content of laminar silicate is in the range from 5 to 100 mg, based on a total mass of the tablet of 1.5 g. 4. Tablet for sucking containing ambroxol according to claim 3, characterised in that the content of laminar silicate is in the range from 20 to 80 mg. 5. Tablet for sucking containing ambroxol according to claim 4, characterised in that the content of laminar silicate is in the range from 30 to 60 mg. 6. Tablet for sucking containing ambroxol according to claim 5, characterised in that the content of laminar silicate is 60 mg. 7. Tablet for sucking containing ambroxol according to one of claims 1 to 6, characterised in that the content of ambroxol hydrochloride is in the range from 1 to 50 mg, based on a total mass of the tablet of 1.5 g. 8. Tablet for sucking containing ambroxol according to claim 7, characterised in that the content of ambroxol hydrochloride is in the range from 5 to 30 mg. 9. Tablet for sucking containing ambroxol according to claim 8, characterised in that the content of ambroxol hydrochloride is in the range from 10 to 25 mg. 10. Tablet for sucking containing ambroxol according to one of claims 1 to 9, characterised in that the polyethyleneglycol has a molecular weight in the range from 3,500 to 20,000. 11.Tablet for sucking containing ambroxol according to claim 10, characterised in that the polyethyleneglycol has a molecular weight in the range from 4,000 to 12,000. 12. Tablet for sucking containing ambroxol according to claim 11, characterised in that the polyethyleneglycol has a molecular weight of 6,000. 13.Tablet for sucking containing ambroxol according to one of claims 1 to 12, characterised in that sorbitol is used as the matrix material. 14. Tablet for sucking containing ambroxol according to one of claims 1 to 13, characterised in that the sodium salt of saccharine is used as the sweetener. 15. Tablet for sucking containing ambroxol according to one of claims 1 to 14, characterised in that peppermint flavouring is used as the flavouring. 16. Process for preparing a tablet for sucking containing ambroxol according to one of claims 1 to 15, characterised in that the individual components are mixed together using process steps known per se and compressed to form a tablet. 17. Process according to claim 16, characterised in that the tablets are prepared by direct compression. 18. Process according to claim 16, characterised in that the laminar silicate is applied by the compression chamber coating method. 19. Use of the tablet for sucking containing ambroxol according to one of claims 1 to 15 for preparing a pharmaceutical composition with secretion-releasing properties.
This group contains 319 subjects. Among them, 220 subjects will be implanted with regular specifications and 99 subjects with narrower, wider or longer ones.
PROBLEM TO BE SOLVED: To obtain a hair tonic and a hair growth agent capable of manifesting excellent hair tonic and hair growth effects and preventing effects on alopecia and providing softening and humectant effects, etc., on the scalp and having high safety over a long period. SOLUTION: This hair tonic and hair growth agent is obtained by including (A) a guanidine derivative represented by formula I [A and B are each a 2-8C alkylene; D is a direct bond or the like; E is H, a lower alkyl or the like; (m) is 1-6; (n) is 0-6; R<1> is H, a lower alkyl or the like] or formula II [(1) is 1-10; G is H, hydroxyl or the like] [e.g. 2-(2-hydroxyethoxy)ethylguanidine] in an amount of preferably 0.001-50.0 wt.%. Furthermore, (B) 0.001-30.0 wt.% of an organic acid (e.g. succinic acid), an inorganic acid or an ester thereof is preferably contained in the hair tonic and hair growth agent. The formulation ratio of the ingredients A to B is preferably (0.5:99.5) to (99.5:0.5) expressed in terms of weight ratio.
Objective: Lower extremity ischemia-reperfusion injury (IRI) may occur with trauma-related vascular injury and various vascular diseases, during the use of a tourniquet, in temporary clamping of the aorta in aortic surgery, or following acute or bilateral acute femoral artery occlusion. Mitochondrial dysfunction and increased basal oxidative stress in diabetes may cause an increase in the effects of increased reactive oxygen species (ROS) and mitochondrial dysfunction due to IRI. It is of great importance to examine therapeutic approaches that can minimize the effects of IRI, especially for patient groups under chronic oxidative stress such as DM. Cerium oxide (CeO2) nanoparticles mimic antioxidant enzymes and act as a catalyst that scavenges ROS. In this study, it was aimed to investigate whether CeO2 has protective effects on skeletal muscles in lower extremity IRI in mice with streptozocin-induced diabetes. Methods: A total of 38 Swiss albino mice were divided into six groups as follows: control group (group C, n = 6), diabetes group (group D, n = 8), diabetes-CeO2 (group DCO, n = 8), diabetes-ischemia/reperfusion (group DIR, n = 8), and diabetes-ischemia/reperfusion-CeO2 (group DIRCO, n = 8). The DCO and DIRCO groups were given doses of CeO2 of 0.5 mg/kg intraperitoneally 30 min before the IR procedure. A 120 min ischemia-120 min reperfusion period with 100% O2 was performed. At the end of the reperfusion period, muscle tissues were removed for histopathological and biochemical examinations. Results: Total antioxidant status (TAS) levels were found to be significantly lower in group DIR compared with group D (p = 0.047 and p = 0.022, respectively). In group DIRCO, total oxidant status (TOS) levels were found to be significantly higher than in group DIR (p < 0.001). The oxidative stress index (OSI) was found to be significantly lower in group DIR compared with group DCO (p < 0.001). Paraoxanase (PON) enzyme activity was found to be significantly increased in group DIR compared with group DCO (p < 0.001). The disorganization and degeneration score for muscle cells, inflammatory cell infiltration score, and total injury score in group DIRCO were found to be significantly lower than in group DIR (p = 0.002, p = 0.034, and p = 0.001, respectively). Conclusions: Our results confirm that CeO2, with its antioxidative properties, reduces skeletal muscle damage in lower extremity IRI in diabetic mice.
The medicamentous form can be used in the treatment of acute and chronic bronchitis. It has the advantages of the liquid forms and has better facilities for storage, shipment and usage. It contains, in wt. pts.: glaucin hydrobromide 0.05-0.30, isomer of ephedrin hydrochloride 0.01-0,35, sweet basic oil 0.01-0,20, citric acid 0.01-2.00, sweetener from 15.0 to 45.0, surfactant from 0.50 to 5.00 or a combination thereof with hydrophilic lipophil from 10 to 18   0.50-5.0, which additionally contains alcohol and preservatives  in the form of powder in which the ratio between the fraction with particle sizes under 0.3 mm and that of from 0.3 to 2.00 mm is 1:4. Semi-solid peroral medicamentous form - gel, is produced by the addition of a condenser from 0,5 to 1.5 wt. pts. and treated water in ration to the powder from 1:2 to 2:1. 4 claims
In December 2019, the first cases of coronavirus disease 2019 (COVID-19) were diagnosed in Wuhan, China. Within a couple of weeks, the highly contagious disease spread across the world, requiring rapid and drastic measures, unparalleled in recent decades. Currently, there have been approximately 97.8 million cases, including 2.1 million deaths, reported to the WHO (website accessed January 25th, 2021, https://covid19.who.int). Data from published epidemiology and virologic studies show that the virus is mainly passed on by respiratory droplets, by direct contact with infected people, or by contact with contaminated objects and surfaces. The severity of the disease greatly differs between people. It ranges from non-symptomatic contamination or minor symptoms, such as a cold or sore throat, to life-threatening pneumonia and death. Especially, the elderly population and people with underlying comorbidities are vulnerable and experience more severe symptoms. In addition, studies have shown that males have a higher mortality risk.

COVID-19 is currently diagnosed using reverse-transcription polymerase chain reaction (RT-PCR). In the beginning of the pandemic the use of chest computed tomography (CT) was more common, since CT can capture imaging features from the lung associated with COVID-19 early in the course of the disease. However, performing a CT-can takes remarkably longer than current RT-PCR tests. While the epidemic continues, the consequences are slowly becoming more apparent. As the true population infection rate is unknown, the proportion of patients requiring hospital admission is difficult to estimate. In a meta-analysis including 1481 unique publications a pooled rate of ICU admission of 10.9% and the pooled rate of mortality was 4.3%. The negative effects of an ICU stay strongly depend on the length of the stay and include, but are not limited to, risk of lung emboly, severe muscle loss, dysphagia and psychological problems, often necessitating a long period of rehabilitation.

To minimize long-term health consequences early prognosis of the severity of the disease would be beneficial. The link between the severity of COVID-19 and mitochondrial DNA (mtDNA), Nuclear SNPs, imaging features and radiomics has not been studied yet. However, literature about mechanistic insights in the functioning of the immune system and its link to genetic variation, including mtDNA, are promising. In addition, studies focusing on imaging features and radiomics have yielded interesting findings.
<P>PROBLEM TO BE SOLVED: To provide a hair reshaping treatment preparation, a hair reshaping treatment setting preparation and a method of hair reshaping treatment, capable of improving hair touch and hair wave sustainability.  <P>SOLUTION: The hair reshaping treatment preparation comprises (a) a copolymer of cystine and a silicone, (b) a solvent and (c) a high-molecular compound other than the component(a). The hair reshaping treatment setting preparation is composed of a 1st agent comprising the components(a), (b) and (c) and a 2nd agent comprising a protein astringent. The method for hair reshaping treatment comprises applying the 1st agent to the hair followed by applying the 2nd agent. It is preferable that the hair reshaping treatment preparation or the 1st agent of the hair reshaping treatment setting preparation contain at least one substance selected from (d) a reducing agent and (e) a protein-denaturating agent which preferably contains at least one compound selected from urea and guanidine hydrochloride.  <P>COPYRIGHT: (C)2004,JPO
OBJECTIVE: This study evaluated the effect of an altered ratio of maternal RBC folate (MRF) to serum vitamin B12 (MB12) on pregnancy and newborn outcomes.
METHODS: Blood samples were collected from pregnant women and the umbilical cord at the time of delivery. Estimations of RBC folate and serum vitamin B12 from maternal and cord blood samples and total homocysteine (HCY) were performed. Maternal and newborn anthropometric parameters like placental weight (PW), head circumference (HC), chest circumference (CC), and body weight (BW) were measured in offsprings after birth. We stratified the pregnant women into six groups (a) vitamin B12 normal and folic acid normal (BNFN)-control group, (b) vitamin B12 normal and folic acid elevated (BNFE), (c) vitamin B12 normal and folic acid deficient (BNFD), (d) vitamin B12 deficient and folic acid normal (BDFN), (e) vitamin B12 deficient and folic acid elevated (BDFE) and (f) vitamin B12 deficient and folic acid deficient (BDFD) based on their levels of RBC folate (MRF) and vitamin B12 (MB12). The expression of the one-carbon metabolism genes (methionine synthase (MS), glycine N-methyltransferase (GNMT), and cystathionine β-synthase (CBS) was also studied in placental tissue by using real-time PCR.
RESULTS: Cord blood RBC folate was significantly reduced in groups BDFE and BDFD as compared to the control group (BNFN). The cord blood vitamin B12 levels were also reduced in the BDFE group as compared to the BDFD. All the newborn parameters viz. PW, HC, CC, and BW, were reduced in the altered MRF/MB12 ratio (low & high vs. normal ratio). Total HCY was significantly elevated in the groups with (BDFE & BDFN) an imbalance of maternal RBC folate and serum vitamin B12 as compared to the control group. Downregulation of one-carbon metabolism genes like MS (p < 0.001), GNMT (p < 0.05), and CBS (p < 0.01) in placental tissue was observed in the high MRF/MB12 ratio group as compared to the normal ratio group. A strong positive correlation was also observed between MRF, MB12, and newborn parameters.
CONCLUSIONS: The altered ratio of folate to vitamin B12 in the maternal blood is associated with adverse growth and development of the newborn.
The fresh gas flow(FGF) is dry and cold in old fashioned anesthesia machine, especially at high folw (above 1 L/min). To the contrary, it has been assumed that the heat and humidity of FGF may be preserved using low FGF (below 1 L/min) during anesthesia or new anesthesia work station. However, it has not been proved yet. We hypothesized that the heat and moisture of FGF may be different in various FGF rate during anesthesia. In addition, it may be different in accordance to anesthesia work station. Therefore, we planed prospective observational study that will demonstrate that the difference of heat and moisture of FGF in different anesthesia work station (Excel; 1st generation anesthesia machine of Datex-Ohmeda Corp., Avance; 2nd generation anesthesia work station of Datex-Ohmeda Corp., Cato; 2nd generation generation anesthesia work station of Drager, Primus; 3rd generation generation anesthesia work station of Drager) and different FGF (0.5, 1, 4 L/min)
A preparation for the transdermal delivery into the body of a patient comprises particles 4 of a formulation that is soluble or biodegradable in the body. The particles are irregular in shape and are angular so that they are capable of penetrating the skin 2 of the patient. Preferably, the formulation comprises a biologically active substance, including at least one excipient. A transdermal patch 6 may comprise the preparation, and may have a body, and means for adhering the body to the skin of a patient. The particles of the preparation may penetrate the outer layer of the skin when subjected to pressure from a roller 8 or an array of blunt-tipped microstructures (12, fig 3). Preferably, the angular particles of the formulation are formed by milling a solid aggregate.
Oral administration of Huai'er granules, 10g once, 3 times a day, continued until the end of the study, intolerable toxicity, withdrawal from the study for any reason, disease progression or death, whichever occurs first; Or the researcher determines that the subject no longer benefits. It is recommended that Huai'er Granules be used for the first time within 14 days-2 months after surgery. Please refer to the drug instructions for specific usage.
PURPOSE:To obtain a solid bath agent, capable of moistening the skin after bathing, providing refreshing touch without giving feeling of stickiness, by blending an oily ingredient with a specific fine powder, solid saccharide and water-soluble emulsifying agent or dispersing agent. CONSTITUTION:A bath agent obtained by blending powder prepared by sprayor freeze-drying an oil-in-water type emulsion containing an oily ingredient, solid saccharide and water-soluble emulsifying agent or dispersing agent selected from a gum agent, water-soluble protein, water-soluble vinyl polymer, anionic surfactant, etc., with fine powder, having <=50wt% settling ratio in water after 24hr and <=3mum particle size and substantially insoluble in water. The fine powder is preferably selected from powder for cosmetics, e.g. acrylic resin, styrene resin, etc. The true specific gravity thereof is preferably close to 1. The solid saccharide is used for converting the dosage form into a solid.
Participants will receive durvalumab plus tremelimumab q3w for four 21-day cycles in combination with chemotherapy followed by maintenance therapy (durvalumab plus pemetrexed maintenance) every 4 weeks (q4w) until disease progression or unacceptable toxicity or treatment discontinuation. During the maintenance therapy phase, participants will receive an additional cycle of durvalumab plus tremelimumab (plus pemetrexed, where applicable) at Week 16.
This protocol proposes that early treatment of Systemic Lupus Erythematous (SLE) may prevent tissue damage and may even lead to long-term remission of disease. This concept is supported by reports of SLE-associated autoimmunity that are detected serologically many years prior to any constitutional symptoms or specific tissue inflammation and immune dysregulation precedes the development of clinically apparent SLE. Belimumab (Benlysta) is an FDA approved medication and is a monoclonal antibody directed against B cell-activating factor (BAFF)/ B Lymphocyte Stimulator (BLyS). B cells maturing in environments with high BAFF levels are more likely to be autoreactive B cells. This is a double-blind placebo controlled trial of belimumab, in patients with early lupus, ie lupus diagnosed within 2 years. Thirty subjects will be randomized (2:1) to receive subcutaneous belimumab weekly or placebo. After a year of treatment, subjects receiving belimumab will be rerandomized (1:1) to receive belimumab or placebo. The primary outcome is B cell autoreactivity. Clinical efficacy including disease activity, flares, attainment of low disease activity or remission as well as surrogate cardiovascular biomarkers will also be assessed.
Low carbohydrate diets, including high-fat, 'ketogenic' diets, have moved to the forefront of popular diets promoted for weight loss in the United States. These diet plans have been aggressively marketed to millions of Americans every year. However, there has been virtually no rigorous study of low carbohydrate, high fat diets either with regard to efficacy in promoting weight loss or effects on cardiovascular risk factors. Because very low carbohydrate diets (i.e., the ketogenic diets) recommend increased intake of fat, and saturated fat, we hypothesized that following one of these diet plans could actually worsen important risk factors for cardiovascular disease. This is an issue of great importance because large numbers of people experiment with low carbohydrate diets despite not knowing their effects on blood pressure, plasma lipid levels, and glucose tolerance. Therefore, we have proposed a clinical trial to test our hypothesis. In this study, we will compare the effects of three months of a ketogenic diet (as promoted by Dr. Robert Atkins) with three months of a weight loss diet that conforms to the American Heart Association dietary guidelines in a group of 100 otherwise healthy obese subjects. During the course of the study, we will determine the effects of diet on 1) body weight, percent fat, and resting metabolic rate, 2) blood pressure, 3) plasma lipids, 4) measures of glucose tolerance, and 5) measures of psychological health and eating behaviors. This pilot study will provide the preliminary data needed to demonstrate the efficacy (or lack thereof) of a popular weight loss technique (i.e., the ketogenic diet) that is currently being criticized by professional organizations. Armed with preliminary data, the investigators plan to further investigate the long-term anthropometric and metabolic effects of ketogenic diets with a larger sample.
This is a pilot trial evaluating the safety and potential efficacy of PEGylated Recombinant Human Hyaluronidase (PEGPH20) plus concurrent Gemcitabine and radiotherapy. Recognizing that PEGPH20 has not been previously delivered with radiotherapy but is unlikely to contribute to increased toxicities, this trial will have an abbreviated sequential dose escalation schema for the first three patients. PEGPH20 will be given twice per week for the first 28 days and then weekly for another 2 weeks during radiotherapy. Gemcitabine will be delivered weekly at the first day of radiotherapy and continued weekly, per published literature. Patients will remain on study for three months. The duration of active treatment with PEGPH20 and Gemcitabine plus radiotherapy will continue for 5-6 weeks. Efficacy outcome will occur 6-8 weeks after the completion of radiotherapy.
Isolation and characterization of human umbilical cord derived mesenchymal stem cells (UMSCs): The culturing and characterization of UMSCs will be performed as documented by Ali and colleagues. Briefly, human umbilical cord tissues along with informed consent forms will be collected from COVID-19- and hepatitis B, C virus-negative women with healthy pregnancies during the Cesarean Section surgery after completion of gestation period. The umbilical cord tissue will be transported in sterile 1x phosphate-buffered saline (PBS) containing penicillin and streptomycin on ice. In the biosafety cabinet, the cord will be washed with 4-5 changes of sterile 1x PBS and placed in a Petri plate with 15ml PBS. The cord will then gently scrap with a surgical blade to remove any dead cells. A 9 cm umbilical cord will be cut into three equal pieces and wash thoroughly to remove blood clots, umbilical cord arteries, and veins. Segments will be washed three times with PBS and minced. The minced pieces will be incubated in 17.5ml of collagenase solution (201 U/ml collagenase type I in serum-free DMEM-HG) in a 50ml conical tube for \~3 hrs in an incubator at 5% CO2, 95% humidity at 37oC. After \~3 hrs, the digested lysate will be passed through strainer and will be diluted three times with 1x PBS. Following centrifugation, the cells will be seeded into two T-25cm2 flasks and will be placed in an incubator at 5% CO2, 95% humidity at 37o C. The flasks will be fed with fresh media (DMEM-HG supplemented with 20% FBS and 1% antibiotic solution) every third day. At around day 18, cells will reach up to 85% confluency and will be transferred in two T-75cm2 flasks with media replaced at alternate days. UMSCs at P3 will be characterized using different specific antibodies. Cells at P3 will be employed for injection in RP patients.
The rapid normalization of hyperglycemia can cause a neuropathy called Diabetes Treatment-Induced Neuropathy (NITD). This phenomenon induces the presence of hyper vascularization and inflammation in contact with the nerve ends.

In another register in patients living with diabetes, it has been observed the development of a rare and devastating complication for the joints called the so-called neuroarthropathy of Charcot (CN). The pathophysiology of CN is not completely known but there is an activation of markers of inflammation and bone remodeling, disruption of the osteoblast and osteoclast system, activation of the RANKL system (Receptor activator of nuclear factor-kappa B ligand) and its antagonist osteoprogesterin (OPG). Inflammation and peripheral hypervascularization therefore seem to be a common link between the two pathologies mentioned (NITD and CN). We have confirmation that the rapid correction of chronic hyperglycemia can trigger (not systematically) NITD, but what about the influence of this rapid correction on the appearance of CN. Furthermore, physical activity (PA) and exercise have long been recognized as the cornerstones of the prevention and management of chronic diseases, due to their beneficial effects on the clinical parameters of various diseases. The practice of PA has a preventive and therapeutic effect against osteoporosis (a disease in which the level of RANKL is particularly high), so there is in theory a preventive effect of the practice of physical activity on the development of CN.